Literature DB >> 19496195

Adjuvant percutaneous radiofrequency ablation of feeding artery of hepatocellular carcinoma before treatment.

Yi-Bin Hou1, Min-Hua Chen, Kun Yan, Jin-Yu Wu, Wei Yang.   

Abstract

AIM: To evaluate the feasibility and efficacy of percutaneous radiofrequency ablation (RFA) of the feeding artery of hepatocellular carcinoma (HCC) in reducing the blood-flow-induced heat-sink effect of RFA.
METHODS: A total of 154 HCC patients with 177 pathologically confirmed hypervascular lesions participated in the study and were randomly assigned into two groups. Seventy-one patients with 75 HCCs (average tumor size, 4.3 +/- 1.1 cm) were included in group A, in which the feeding artery of HCC was identified by color Doppler flow imaging, and were ablated with multiple small overlapping RFA foci [percutaneous ablation of feeding artery (PAA)] before routine RFA treatment of the tumor. Eighty-three patients with 102 HCC (average tumor size, 4.1 +/- 1.0 cm) were included in group B, in which the tumors were treated routinely with RFA. Contrast-enhanced computed tomography was used as post-RFA imaging, when patients were followed-up for 1, 3 and 6 mo.
RESULTS: In group A, feeding arteries were blocked in 66 (88%) HCC lesions, and the size of arteries decreased in nine (12%). The average number of punctures per HCC was 2.76 +/- 1.12 in group A, and 3.36 +/- 1.60 in group B (P = 0.01). The tumor necrosis rate at 1 mo post-RFA was 90.67% (68/75 lesions) in group A and 90.20% (92/102 lesions) in group B. HCC recurrence rate at 6 mo post-RFA was 17.33% (13/75) in group A and 31.37% (32/102) in group B (P = 0.04).
CONCLUSION: PAA blocked effectively the feeding artery of HCC. Combination of PAA and RFA significantly decreased post-RFA recurrence and provided an alternative treatment for hypervascular HCC.

Entities:  

Mesh:

Year:  2009        PMID: 19496195      PMCID: PMC2691496          DOI: 10.3748/wjg.15.2638

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  23 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

2.  Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow. Comparison with standard percutaneous radiofrequency ablation therapy.

Authors:  Takahiro Yamasaki; Fumie Kurokawa; Hitoshi Shirahashi; Noriyoshi Kusano; Kouji Hironaka; Kiwamu Okita
Journal:  Cancer       Date:  2002-12-01       Impact factor: 6.860

3.  Percutaneous radiofrequency ablation of hepatic tumors during temporary venous occlusion.

Authors:  T de Baere; B Bessoud; C Dromain; M Ducreux; V Boige; N Lassau; T Smayra; B V Girish; A Roche; D Elias
Journal:  AJR Am J Roentgenol       Date:  2002-01       Impact factor: 3.959

4.  Hepatocellular carcinoma: long-term results of combined treatment with laser thermal ablation and transcatheter arterial chemoembolization.

Authors:  C M Pacella; G Bizzarri; P Cecconi; B Caspani; F Magnolfi; A Bianchini; V Anelli; S Pacella; Z Rossi
Journal:  Radiology       Date:  2001-06       Impact factor: 11.105

5.  Effect of vascular occlusion on radiofrequency ablation of the liver: results in a porcine model.

Authors:  S B Chinn; F T Lee; G D Kennedy; C Chinn; C D Johnson; T C Winter; T F Warner; D M Mahvi
Journal:  AJR Am J Roentgenol       Date:  2001-03       Impact factor: 3.959

6.  Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions.

Authors:  T Livraghi; S N Goldberg; S Lazzaroni; F Meloni; T Ierace; L Solbiati; G S Gazelle
Journal:  Radiology       Date:  2000-03       Impact factor: 11.105

7.  Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies.

Authors:  A S Pearson; F Izzo; R Y Fleming; L M Ellis; P Delrio; M S Roh; J Granchi; S A Curley
Journal:  Am J Surg       Date:  1999-12       Impact factor: 2.565

8.  Radiofrequency ablation in the treatment of small hepatocellular carcinomas: comparison of the radiofrequency effect with and without chemoembolization.

Authors:  Mikiya Kitamoto; Masaru Imagawa; Hiroyasu Yamada; Chiyuki Watanabe; Masaaki Sumioka; Osamu Satoh; Masaru Shimamoto; Michiyo Kodama; Shojiro Kimura; Keiko Kishimoto; Yuzo Okamoto; Yasuhiko Fukuda; Kiyohiko Dohi
Journal:  AJR Am J Roentgenol       Date:  2003-10       Impact factor: 3.959

9.  Percutaneous sonographically guided saline-enhanced radiofrequency ablation of hepatocellular carcinoma.

Authors:  Antonio Giorgio; Luciano Tarantino; Giorgio de Stefano; Vincenzo Scala; Giulia Liorre; Ferdinando Scarano; Anna Perrotta; Nunzia Farella; Vincenza Aloisio; Nicola Mariniello; Carmine Coppola; Giampiero Francica; Giovanna Ferraioli
Journal:  AJR Am J Roentgenol       Date:  2003-08       Impact factor: 3.959

10.  Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma.

Authors:  Lawrence E Harrison; Baburao Koneru; Phil Baramipour; Adrian Fisher; Alison Barone; Dorian Wilson; Andrew Dela Torre; Kyunghee C Cho; Daniel Contractor; Maria Korogodsky
Journal:  J Am Coll Surg       Date:  2003-11       Impact factor: 6.113

View more
  7 in total

1.  Radiofrequency ablation of hepatocellular carcinoma in difficult locations: Strategies and long-term outcomes.

Authors:  Wei Yang; Kun Yan; Gong-Xiong Wu; Wei Wu; Ying Fu; Jung-Chieh Lee; Zhong-Yi Zhang; Song Wang; Min-Hua Chen
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

Review 2.  Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.

Authors:  Davide Roccarina; Avik Majumdar; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-03-10

3.  Vastatin, an Endogenous Antiangiogenesis Polypeptide That Is Lost in Hepatocellular Carcinoma, Effectively Inhibits Tumor Metastasis.

Authors:  Zan Shen; Chen Yao; Zifeng Wang; Lu Yue; Zheping Fang; Hong Yao; Feng Lin; Hui Zhao; Yuan-Jue Sun; Xiu-Wu Bian; Wenqi Jiang; Xiaomei Wang; Yi Li; Gang Lu; Wai Sang Poon; Hsiang-Fu Kung; Marie Chia-Mi Lin
Journal:  Mol Ther       Date:  2016-03-10       Impact factor: 11.454

Review 4.  Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis.

Authors:  Avik Majumdar; Davide Roccarina; Douglas Thorburn; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2017-03-28

5.  Percutaneous radiofrequency ablation of tumor feeding artery before target tumor ablation may reduce local tumor progression in hepatocellular carcinoma.

Authors:  Ya-Ting Cheng; Wen-Juei Jeng; Chen-Chun Lin; Wei-Ting Chen; I-Shyan Sheen; Chun-Yen Lin; Shi-Ming Lin
Journal:  Biomed J       Date:  2016-12-24       Impact factor: 4.910

6.  Feeding artery ablation before radiofrequency ablation for hepatocellular carcinoma may reduce critical recurrence.

Authors:  Ryo Shimizu; Hideyuki Tamai; Yoshiyuki Ida; Shuya Maeshima; Naoki Shingaki; Takao Maekita; Mikitaka Iguchi; Masayuki Kitano
Journal:  JGH Open       Date:  2021-03-01

7.  Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma.

Authors:  Bruno Bockorny; Andrea J Bullock; Thomas A Abrams; Salomao Faintuch; David C Alsop; S Nahum Goldberg; Muneeb Ahmed; Rebecca A Miksad
Journal:  Dig Dis Sci       Date:  2021-07-23       Impact factor: 3.487

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.